Recruiting

Testing a new cancer treatment for relapsed lung cancer

Plain-English translation of NCT07099898 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new medication called GSK5764227 (also known as Ris-Rez) to see if it can help people whose small cell lung cancer has come back after their first round of treatment. The medication works by targeting specific proteins on cancer cells to slow their growth and spread. Researchers will compare how well this treatment works compared to the standard chemotherapy currently used.

Small cell lung cancer often returns after initial treatment, and doctors need better options to help patients live longer and healthier lives. This trial exists to see whether this new targeted treatment could offer a meaningful improvement over the current standard care.

Do you qualify?

You likely qualify if…

you are 18 years of age or older
you have been diagnosed with extensive-stage small cell lung cancer that has come back after previous treatment
you have already received at least one prior round of platinum-based chemotherapy and immunotherapy with documented cancer progression
your cancer has measurable tumors that can be tracked on imaging scans
you have adequate organ function and are well enough to tolerate treatment (ECOG performance status of 0 or 1)

You likely don't qualify if…

you have certain rare types of small cell lung cancer (complex or transformed SCLC)
you have untreated brain metastases or other specific brain involvement
you have active, uncontrolled heart disease or recent significant bleeding problems
you have active hepatitis, HIV, or serious active infections requiring treatment
you have significant lung disease (such as uncontrolled asthma or COPD) or a history of interstitial lung disease

What participation looks like

If you join this study, you will be randomly assigned to receive either the new medication or the standard chemotherapy (). You will have regular clinic visits to receive your treatment, have blood tests and scans to check how your cancer is responding, and be monitored for any side effects. The study will track how well the treatment works and how you tolerate it over time.

AI-generated summary from trial data · Sep 3, 2026 · Not medical advice

Testing a new cancer treatment for relapsed lung cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations